2017Jurnal Vektor PenyakitOpen access

Review Artikel : Perkembangan Vaksin untuk Schistosoma japonicum

Anis Nurwidayati

Open full text 0 citations

Abstract

Schistosomiasis infects 261 million people in 78 countries with 600 million people at risk of infection. Schistosomiasis in Indonesia is due to blood trematode Schistosoma japonicum and Oncomelania hupensis lindoensis snail as intermediate host .Schistosomiasis control is conducted by the management of environment as well as treatment with praziquantel. The long periode and continously drug use may result in drug resistance. Based on these, vaccines against schistosomiasis, as schistosomiasis control strategies in the future, is needed. This review was aimed to describe some of the vaccine candidates against S. japonicum with their level of efficacy, which composed by many schistosomiasis vaccine-related scientific literature. Schistosomiasis vaccine candidate proteins showed varying levels of efficacy and no one has the most potential. Although the development of vaccines against schistosomiasis is quite difficult, the research must still be continued

About this research paper

What this paper is about

Schistosomiasis infects 261 million people in 78 countries with 600 million people at risk of infection. Schistosomiasis in Indonesia is due to blood trematode Schistosoma japonicum and Oncomelania hupensis lindoensis snail as intermediate host .Schistosomiasis control is conducted by the management of environment as well as treatment with praziquantel. The long periode and continously drug use may result in drug resistance. Based on these, vaccines against schistosomiasis, as schistosomiasis control strategies in the future, is needed. This review was aimed to describe some of the vaccine candidates against S. japonicum with their level of efficacy, which composed by many schistosomiasis vaccine-related scientific literature. Schistosomiasis vaccine candidate proteins showed varying levels of efficacy and no one has the most potential. Although the development of vaccines against schistosomiasis is quite difficult, the research must still be continued

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Schistosomiasis infects 261 million people in 78 countries with 600 million people at risk of infection. Schistosomiasis in Indonesia is due to blood trematode Schistosoma japonicum and Oncomelania hupensis lindoensis snail as intermediate host .Schistosomiasis control is conducted by the management of environment as well as treatment with praziquantel. The long periode and continously drug use may result in drug resistance. Based on these, vaccines against schistosomiasis, as schistosomiasis control strategies in the future, is needed. This review was aimed to describe some of the vaccine candidates against S. japonicum with their level of efficacy, which composed by many schistosomiasis vaccine-related scientific literature. Schistosomiasis vaccine candidate proteins showed varying levels of efficacy and no one has the most potential. Although the development of vaccines against schistosomiasis is quite difficult, the research must still be continued

Key concepts: Schistosoma japonicum, Schistosomiasis, Praziquantel, Oncomelania hupensis, Schistosoma, Immunology, Biology, Medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Review Artikel : Perkembangan Vaksin untuk Schistosoma japonicum — Research Paper | ScholarLens